- Home
- QCRH vs COLL Comparison
QCRH vs COLL Comparison
Compare QCRH & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- COLL
- Stock Information
- Founded
- QCRH 1993
- COLL 2002
- Country
- QCRH United States
- COLL United States
- Employees
- QCRH N/A
- COLL N/A
- Industry
- QCRH Major Banks
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- QCRH Finance
- COLL Health Care
- Exchange
- QCRH Nasdaq
- COLL Nasdaq
- Market Cap
- QCRH 1.1B
- COLL 1.1B
- IPO Year
- QCRH 1993
- COLL 2015
- Fundamental
- Price
- QCRH $76.31
- COLL $36.06
- Analyst Decision
- QCRH Buy
- COLL Strong Buy
- Analyst Count
- QCRH 4
- COLL 4
- Target Price
- QCRH $90.00
- COLL $44.25
- AVG Volume (30 Days)
- QCRH 111.5K
- COLL 319.9K
- Earning Date
- QCRH 10-22-2025
- COLL 11-06-2025
- Dividend Yield
- QCRH 0.32%
- COLL N/A
- EPS Growth
- QCRH 3.93
- COLL N/A
- EPS
- QCRH 7.15
- COLL 1.06
- Revenue
- QCRH $336,623,000.00
- COLL $707,007,000.00
- Revenue This Year
- QCRH N/A
- COLL $21.29
- Revenue Next Year
- QCRH $18.11
- COLL $3.36
- P/E Ratio
- QCRH $10.59
- COLL $33.77
- Revenue Growth
- QCRH N/A
- COLL 22.61
- 52 Week Low
- QCRH $60.83
- COLL $23.23
- 52 Week High
- QCRH $96.08
- COLL $39.95
- Technical
- Relative Strength Index (RSI)
- QCRH 55.79
- COLL 56.27
- Support Level
- QCRH $71.69
- COLL $35.33
- Resistance Level
- QCRH $77.85
- COLL $36.58
- Average True Range (ATR)
- QCRH 2.48
- COLL 1.06
- MACD
- QCRH 0.52
- COLL 0.24
- Stochastic Oscillator
- QCRH 82.49
- COLL 79.83
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.